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Abstract
Purpose The timing of sentinel lymph node biopsy
(SLNB) in the context of neoadjuvant systemic therapy
(NAST) in breast cancer is still controversial. SLNB before
NAST has been evaluated in few single-institution studies
in which axillary lymph node dissection (ALND), however,
was commonly not performed in case of a negative SLNB.
We investigated the potential clinical relevance of SLNB
before NAST by performing ALND in all patients after
NAST.
Methods This national multicenter trial prospectively
enrolled clinically node-negative breast cancer patients
planned for NAST at 13 recruiting Swedish hospitals
between October 2010 and December 2015. SLNB before
NAST was followed by ALND after NAST in all
individuals. Repeat SLNB after NAST was encouraged but
not mandatory.
Results SLNB before NAST was performed in 224
patients. The identification rate was 100% (224/224). The
proportion of patients with a negative SLNB before NAST
but positive axillary lymph nodes after NAST was 7.4%
(nine of 121 patients, 95% CI 4.0–13.5). Among those with
a positive SLNB before NAST, 23.2% (86/112) had further
positive lymph nodes after NAST.
Conclusions In clinically node-negative patients, SLNB
before NAST is highly reliable. With this sequence, ALND
and regional radiotherapy can be safely omitted in patients
with a negative SLNB provided good clinical response to
NAST. Additionally, SLNB-positive patients upfront will
receive correct nodal staging unaffected by NAST and be
consequently offered adjuvant locoregional treatment
according to current guidelines pending the results of
ongoing randomized trials.
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Introduction
Sentinel lymph node biopsy (SLNB) is gold standard for
axillary nodal staging in early-stage breast cancer. Long-
term follow-up has not shown any significant difference in
survival or regional control when omitting axillary lymph
node dissection (ALND) after a negative SLNB [1]. Also in
larger tumors, SLNB has comparable accuracy [2].
Lately, indications for neoadjuvant systemic therapy
(NAST) have been extended to not only encompass locally
advanced but also early operable stages of the disease.
Since then, only half of patients planned for NAST show
nodal involvement at presentation, and an additional
20–40% will be downstaged to node negativity during
treatment [3].
ALND is the traditional staging procedure in the
neoadjuvant setting but is associated with significant arm
morbidity which is further aggravated by regional radio-
therapy [4]. To mitigate this, SLNB has been studied in
several trials outlined below; the timing in relation to
NAST, however, remains controversial.
SLNB before NAST has been evaluated in clinically
node-negative (cN0) patients in a number of small single-
center studies with excellent identification rates (IR). False
negative rates (FNR) were as low as 0% in those few
studies in which ALND was performed after a negative
SLNB [5–7]. However, the majority of studies omitted
ALND after a negative SLNB and reported the absence of
axillary recurrences after a median follow-up period of
11–36 months [8–10], which is arguably short in the con-
text of breast cancer.
SLNB after NAST has mostly been performed in clini-
cally node-positive (cN1) patients at presentation [11] or
included in meta-analyses reporting combined results for
cN0 and cN1 patients [12, 13]. Classe et al. reported on a
prospective multicenter study in which both IR and FNR
for SLNB after NAST were better for patients with cN0
compared to cN1 disease at presentation [14].
SLNB before NAST in cN0 patients provides axillary
staging unaffected by primary systemic therapy and can
guide treatment decisions regarding appropriate chemo-
and radiotherapy. According to the updated 2014 ASCO
guidelines, as well as the NCCN guidelines from 2016,
women with cN0 operable breast cancer may be offered
SLNB either before or after NAST in the absence of evi-
dent axillary nodal disease [15, 16]. With the purpose of
avoiding two surgical procedures and in order to take
advantage of the nodal downstaging effect of NAST,
SLNB after NAST has gained popularity. However, clini-
cally node-negative patients with undiagnosed metastases
upfront are at increased risk of a false-negative SLNB after
NAST in at least 11% and consequently locoregional
undertreatment [17]. Staging of the axilla upfront by
ultrasound and fine needle aspiration, however, cannot
replace SLNB as it is associated with a sensitivity of only
21–25% in finding axillary metastasis in clinically node-
negative patients [18, 19].
Thus, the primary aim was to study the agreement of the
SLNB result before NAST with the ALND result after
NAST in cN0 breast cancer patients, irrespective of the
result of the SLNB upfront. The secondary aim was to
evaluate the feasibility and false negative rate of repeat
SLNB.
Methods
This Swedish prospective multicenter trial recruited con-
secutive patients with biopsy-proven invasive breast cancer
planned for NAST from 20 invited hospitals, of which 13
actively recruited patients to the present arm of the trial
between October 1, 2010 and December 31, 2015. Ultra-
sound of the axilla was performed and in case of suspicious
lymph nodes, fine needle aspiration cytology (FNAC) was
recommended. Patients were recruited into two arms
depending on their axillary status pre-NAST.
Patients with proven axillary lymph node metastasis
were directed into the second arm of this trial which will be
reported separately.
In the here reported arm of the trial, only cN0 patients
were eligible.
SLNB was performed before NAST and ALND after
NAST in all patients. A repeat SLNB, regardless of the
primary SLNB result, was encouraged in conjunction with
ALND. Exclusion criteria were inflammatory breast can-
cer, allergic reactions to Patent Blue V or radiolabeled
colloid, and inability to give informed consent.
For more details see Clinical.Trials.gov identifier
NCT02031042.
Lymphatic mapping technique
Preoperative lymphoscintigraphy was optional. Lymphatic
mapping was performed with 99mTechnetium-labeled
nanocolloid, Patent Blue V, or a combination of both. The
definition of a sentinel lymph node (SLN) was the hottest
node, any node with more than 10% of the radioactivity of
the hottest node, any blue node or clinically suspicious
nodes on digital exploration.
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Surgery
Breast surgery was either breast-conserving surgery or
mastectomy. All patients underwent a standard ALND of
levels I and II after NAST.
Neoadjuvant systemic therapy
Both neoadjuvant chemotherapy and endocrine therapy
were eligible treatments. Standard chemotherapy regimens
contained anthracyclines and taxanes and were given either
according to regional guidelines or within current study
protocols. Endocrine therapy consisted of aromatase inhi-
bitors. Anti-HER2 therapy was given in combination with
taxane-based chemotherapy. Altered or interrupted treat-
ment was recorded together with the reason for disruption.
Response evaluation
Clinical and radiological response was evaluated by com-
paring findings in the breast and axillary lymph nodes at
diagnosis with those before definitive surgery. Classifica-
tion was according to the UICC criteria [20] apart from
radiological partial response which was defined as more
than 30% decrease in tumor load measured on the greatest
diameter according to the RECIST-criteria [21]. Pathologic
response was graded as described by Sataloff et al. evalu-
ating tumor (T) and nodes (N) separately [22], see Table 4.
Post-NAST stage classification (ypTNM) was based on
the 7th edition of the AJCC staging system [23]. Pathologic
complete response was defined as no residual invasive
disease in the breast and axillary lymph nodes (ypT0/is
ypN0). Presence of isolated tumor cells (ITC, ypN0(i?))
was not defined as nodal pCR [24].
Pathologic assessment of lymph nodes
Lymph nodes were handled and assessed according to
Swedish National Guidelines for Pathologists. All SLNs
were fixed in formalin, sliced at 2 mm intervals, and
embedded in paraffin. Each paraffin block was then sec-
tioned at three 200 lm levels, and each level was stained
with hematoxylin and eosin. If no cancer cells were
detected, immunohistochemical staining with cytokeratin
was recommended. SLN metastases were classified
according to the 7th edition of the AJCC breast cancer
staging manual [25].
Definitions
Clinical tumor stage was based on pre-NAST radiological
size measured by mammography or ultrasound. The iden-
tification rate was defined as the number of patients with a
successfully identified SLN divided by the total number of
patients in whom an SLNB was attempted. The term ‘‘false
negative rate’’ (FNR) was here adapted to the neoadjuvant
setting, and was defined as the proportion of patients with a
negative SLNB pre-NAST but at least one positive axillary
lymph node post-NAST, divided by all node-positive
patients with an identified SLNB pre-NAST [26]. FNR in
repeat SLNB was defined as the proportion of patients with
a negative SLNB after NAST but at least one positive non-
sentinel node after NAST, divided by all patients with at
least one involved node among patients with at least one
identified repeat SLN. Accuracy was defined as the pro-
portion of patients with a true-positive or true-negative
SLNB out of all patients with a successful SLNB.
Statistical analysis
Sample size calculation was performed prior to the initia-
tion of this trial. With an estimated 50% of all patients
having a positive SLNB, and a proposed sample size of 200
patients, estimation of the FNR in SLNB before NAST is
based on 100 individuals. If assuming a true ‘‘false nega-
tive rate’’ of SLNB before NAST of 8%, a power of 80%
will then be achieved with reported confidence intervals
(CI) of ±7 percentages.
Descriptive statistics are presented as median values
with their ranges for continuous variables and as distribu-
tions with their percentages for categorical variables.
Comparison of groups according to sentinel lymph node
status was performed after exploring normal data distri-
bution. For comparison of non-parametric continuous data,
the Mann–Whitney U test was applied. For comparison of
non-parametric categorical data, Fisher’s exact test was
used. A p value of\ 0.05 was considered statistically
significant. The statistical software programme IBM SPSS
Statistics for Windows Version 23.0 (Armonk, NY, USA)
was used for all analyses.
Results
Patients
Of an initial 264 eligible patients, 40 withdrew their con-
sent or were excluded for other reasons. A CONSORT
diagram is presented in Fig. 1. Thus, 224 patients from 13
recruiting hospitals operated by 67 surgeons were available
for analysis. Median age was 47 years (range 22–78).
Median radiological tumor size at diagnosis was 39 mm
(range 9–127). An axillary ultrasound was performed in
97.3% (218/224) of the patients. Clinicopathologic and
treatment characteristics of the trial population are reported
in Table 1.
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Treatment
The majority of patients received anthracycline plus tax-
ane-based chemotherapy (199/224, 88.8%). Only two
patients 0.9% (2/224) had neoadjuvant endocrine therapy.
Neoadjuvant systemic therapy regimens are presented in
Table 1.
In 22 patients, treatment was interrupted prematurely
due to intolerable side effects (9), toxicity (6), tumor pro-
gress (5), lack of response (1), or partus (1). In 49 patients,
treatment was altered due to intolerable side effects (27),
toxicity (10), lack of response (8), or tumor progress (4). Of
all HER2-positive patients, 94.4% (68/72) received tar-
geted treatment, 16.2% (11/68) of whom received dual
antibodies. Breast-conserving surgery was performed in 65
of 224 patients (29.0%).
SLN detection before NAST
Lymphatic mapping was performed using dual mapping in
95.5% (213/223) of patients. At least one SLN was iden-
tified in all patients pre-NAST, with a median of two SLNs
(range 1–11). Half of all patients had a positive SLNB
(112/224), 85.7% of whom (96/112) had at least one
macrometastasis (median 1, range 1–6). After NAST, the
median number of retrieved axillary lymph nodes, includ-
ing repeat SLNs if any, was 10 (range 1–31), and the
median number of positive axillary lymph nodes was two
(range 1–12). Almost 77% (86/112) of patients with a
positive SLNB before NAST had no positive axillary
lymph nodes after NAST.
False negative rate
A comparison of SLN status before NAST and overall
axillary lymph node status (including pre- and post-NAST)

























Fig. 1 CONSORT diagram. NAST neoadjuvant systemic therapy,
SLNB sentinel lymph node biopsy, ALND axillary lymph node
dissection
Table 1 Clinicopathologic and treatment characteristics of the trial
population
No. (%)
No. of patients 224















ER positive 137 (61.2)




Anthracycline plus taxane 199 (88.8)
Anthracycline only 10 (4.5)
Other type 13 (5.8)
Aromatase inhibitor 2 (0.9)
ER estrogen receptor, PR progesterone receptor, HER2 human epi-
dermal growth factor receptor 2
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is presented in Table 2. Nine patients had a negative SLNB
before NAST but at least one positive lymph node in the
axilla after NAST, resulting in a FNR of 7.4% (95% CI
4.0–13.5). Among these cases, the maximum number of
positive lymph nodes was two, and the median number of
retrieved axillary lymph nodes after NAST was nine (range
5–12). Details on those nine patients are displayed in
Table 3.
There was no significant difference between patients
with a false-negative compared to a true-positive or true-
negative SLNB regarding any of those factors listed in
Table 1. Only 22.2% of patients with a false-negative
SLNB upfront achieved a complete clinical response (best
clinical or radiological) in the breast, compared with 42.3%
in the true-positive/true-negative group (p = 0.089). For
complete pathologic response in the breast, the corre-
sponding figures were 11.1 and 30.7%, respectively
(p = 0.036), see Table 4.
Of all patients with a negative SLNB before NAST,
92.0% (103/112) remained node-negative after NAST
including one patient with ypN0(i?). A complete patho-
logic response in the breast (ypT0/is) was achieved in
33.9% (38/112), and a complete pathologic response in
both axillary lymph nodes and breast (ypCR) was achieved
in 33.0% (37/112). Among patients with a positive SLNB
before NAST, 76.8% (86/112) had only negative nodes
after NAST including two patients with ypN0(i?). A
complete pathologic response in the breast (ypT0/is), and
in both breast and axillary lymph nodes (ypCR), was
achieved in 25.0% (28/112; p = 0.19) and 24.1% (27/112;
p = 0.18), respectively.
Repeat SLNB after NAST
In 98 patients, a repeat SLNB was attempted after NAST.
Dual mapping was performed in 86.7% (85/98). In 69.4%
(68/98), at least one SLN was identified. The median
number of SLNs retrieved was 1 (range 1–5). The FNR for
repeat SLNB was 25.0% (3/12). A comparison of SLN
status after NAST and corresponding non-SLNs after
NAST is presented in Table 5.
Discussion
We here present data from a prospective multicenter trial
recruiting cN0 breast cancer patients planned for NAST at
13 Swedish hospitals. The excellent IR agrees with earlier
studies evaluating SLNB before NAST [5–10] and con-
firms that the SLNB concept works well both in high- and
low-volume hospitals. The high IR is probably due to a
high rate of dual tracer use, underlining this method as the
recommended technique. The much lower IR in repeat
SLNB after NAST may reflect obstruction of lymph vessels
with inflammatory debris secondary to NAST and post-
operative scarring; this corresponds well with the results of
the German four-armed SENTINA study in which the
repeat SLNB IR was only 60.8% [26]. There is a possibility
that the true IR might be even lower than reported in our
trial since it cannot be ruled out that the repeat SLNB may
have been identified only on the excised ALND specimen
ex vivo instead of prior to ALND.
The proportion of patients with a negative SLNB before
NAST but positive axillary lymph nodes after NAST was
7.4% in this trial, in which ALND was performed in all
patients irrespective of the result of the SLNB upfront. This
is comparable to the FNR in early-stage breast cancer [27],
even though it cannot be ruled out that nodal metastases
could have developed during the course of NAST in our
trial, and thus, a direct comparison may be difficult. It
should also be taken into account that the confidence
interval around the point estimate is rather broad with 224
evaluated patients, as pointed out in the sample size cal-
culation. In earlier publications, validating SLNB before
NAST by post-NAST ALND, the FNR was 0%; however,
these were all small single-institution studies at dedicated
centers [5–7]. Based on the larger sample size and multi-
center design in our trial we would suspect the true FNR to
be closer to 7% than to 0% despite some uncertainty in the
estimation. A false-negative SLNB, if not followed by an
ALND, leads to incorrect nodal staging and inappropriate
decision-making regarding adjuvant locoregional therapy.
These individuals run the risk of being undertreated since
an ALND will not be performed and adjuvant regional
radiotherapy is unlikely to be recommended.
In our trial, one of the nine patients with a false-negative
SLNB progressed clinically and/or radiologically during
NAST, which was consequently interrupted after three
cycles. Fewer patients with a false-negative SLNB tended
to achieve a complete clinical response in the breast, and
significantly fewer had a complete pathological response in
the breast than those with a true-positive or true-negative
Table 2 Cross tabulation of SLN status before NAST and overall
axillary nodal status
SLNB before NAST Overall axillary nodal statusa
Positive Negative Total
Positive 112 0 112
Negative 9 103 112
Total 121 103 224
a Lymph node status in SLNs before, SLNs after NAST if performed,
and non-SLNs after NAST. Sensitivity 92.6% (112/121), specificity
100.0% (103/103), and accuracy 96.0 % (215/224). SLN sentinel
lymph node, SLNB sentinel lymph node biopsy, NAST neoadjuvant
systemic therapy
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SLNB. We therefore conclude that the decision to omit
ALND after a negative SLNB upfront should be recon-
sidered if the clinical and/or radiological response has been
poor. The axillary tumor burden, however, was low with a
maximum of two macrometastases in the completion
ALND after NAST, and it is thus unclear whether false
negativity translates into a higher incidence of locoregional
recurrences (LRR).
The median number of retrieved axillary lymph nodes
after NAST was ten in this trial which is rather low but
corresponds with earlier reports [28, 29]. We have no
reason to interpret these numbers as inadequate axillary
dissections. We rather believe they represent treatment
effects and possibly technical challenges in analyzing the
axillary pathology specimens after NAST.
The proportion of patients in our trial with a false-
negative repeat SLNB was 25%, which is much lower than
the 51.6% seen in arm B in the prospective four-armed

















Total number of axillary
metastases after NAST
13 2 N1 10 1
20 2 Yes, one N0 N1 7 1
87 2 N1 12 1
95 1 Yes, one N1 N1mi 9 2
108 1 N1 9 2
167 3 Yes, zero Not identified N1mi 5 1
196 1 Yes, two N1 N0 9 1
408 4 N1 10 2
439 1 N1 8 2
SLN sentinel lymph node, SLNB sentinel lymph node biopsy, NAST neoadjuvant systemic therapy, N1 macrometastasis, N1mi micrometastasis




True pos and true neg (%) False neg (%) p
No. of patients 215 9
Best clinical or radiological response (ycT)
Complete response 91 (42.3) 2 (22.2)
Partial response 101 (47.0) 6 (66.7)
No change 21 (9.8) 0 (0)
Progress 2 (0.9) 1 (11.1) 0.089
Pathological response (ypT)
Sataloff T–A 66 (30.7) 1 (11.1)
Sataloff T–B 77 (35.8) 1 (11.1)
Sataloff T–C 56 (26.0) 5 (55.6)
Sataloff T–D 16 (7.4) 2 (22.2) 0.036
Complete response: The disappearance of all known disease, Partial clinical response: 50% or more
decrease in total tumor load, No change: A 50% decrease in total tumor size cannot be established nor an
increase of 25%, Progressive disease: 25% or more increase in size of one or more measurable lesions.
Partial radiological response according to RECIST-criteria: 30% or more decrease in the sum of the longest
diameter (LD) in target lesions, taking as reference the baseline sum LD. Sataloff T–A: Total or near total
therapeutic effect, Sataloff T–B:[50% therapeutic effect but less than total or near total, Sataloff T–C:
\50% therapeutic effect, but effect evident, Sataloff T–D: NO therapeutic effect. SLN sentinel lymph node
Table 5 Cross tabulation of repeat SLNB and axillary-involved
nodes after NAST
Repeat SLNB Overall axillary nodal status after NASTa
Positive Negative Total
Positive 9 0 9
Negative 3 56 59
Total 12 56 68
a Overall axillary lymph node status in SLNs and non-SLNs after
NAST SLNB, sentinel lymph node biopsy, NAST neoadjuvant sys-
temic therapy
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SENTINA study by Kuhn et al. [26]. Contradictory to these
results, Khan et al. reported on a FNR of only 4.5%, but
repeat SLNB was only performed in 18 out of 33 indi-
viduals [30]. We therefore agree, despite relatively few
patients in our trial, with the conclusion of Kuhn et al. in
that a repeat SLNB cannot be recommended.
There is a lack of prospective data on LRR after NAST,
especially after SLNB as the only staging procedure. In a
recent retrospective study, clinically node-negative patients
after NAST (ycN0) with a negative SLNB after NAST and
no ALND were evaluated after five years of follow-up.
Patients being cN0 or cN1/N2 before NAST had equally
good overall survival. Only one patient developed a
regional recurrence in the cN1/N2 group. In cN1/N2
patients with residual tumor burden in the breast, however,
a negative SLNB after NAST had no influence on survival.
The authors discussed if this was a consequence of higher
false negative rates in this group with residual disease in
the breast [31].
In early-stage breast cancer, the locoregional recurrence
rate after a negative SLNB without ALND is low [32]
despite false negative rates of 5–10% [27]. Also with a
limited tumor burden, patients randomized to no ALND
after a positive SLNB do not have a worse outcome than
patients with an ALND performed [33, 34]. Even though
these studies were underpowered to detect small yet clin-
ically relevant differences, and only patients with breast-
conserving surgery who received whole-breast adjuvant
radiotherapy were eligible, they have resulted in significant
practice changes. Translated into the neoadjuvant setting,
these results would appear to support the use of SLNB
before NAST and the omission of ALND in the case of
SLN metastases in breast-conserving surgery, as 96–97%
of patients in above-mentioned trials received adjuvant
chemotherapy. They are not, however, adapted to support
the omission of an ALND after a positive SLNB after
NAST. Results from trials regarding this specific situation
are still pending. On the other hand, patients fulfilling
Z0011 criteria before NAST may, if SLNB is delayed until
after NAST, remain undetected; some of them will convert
into SLN-negative cases with an increased inherent FNR
[17], others will remain SLN positive and, according to
most current guidelines, undergo ALND. The first scenario
results in a clear risk of the omission of locoregional
treatment, and the second in unnecessarily extensive axil-
lary surgery.
In cN0 patients planned for NAST, the timing of SLNB
can be either before or after NAST. According to the
ASCO guidelines from 2014 and the NCCN guidelines
from 2016, both alternatives are valid [15, 16]. The
advantages in performing SLNB upfront is that IR is
excellent and nodal staging unaffected by NAST [26]. A
correct nodal staging before NAST may help in deciding
on optimal chemotherapy before and the most adequate
locoregional treatment after NAST. However, two surgical
interventions are mandated. SLNB after NAST has the
advantage of only one operation, and more patients can be
spared an ALND due to nodal downstaging in 20–40%
[3]—if ALND is omitted in SLN-negative cases after
NAST. The disadvantages, however, are lower identifica-
tion rates and higher false negative rates after NAST and
uncertainty on pre-treatment nodal stage, making decisions
on axillary surgery and adjuvant radiotherapy more diffi-
cult with an obvious risk of undertreatment [17]. There are
two ongoing randomized trials that will hopefully offer
some answers to these questions [35]. Until then, per-
forming SLNB upfront in clinically node-negative patients
seems a safe and clinically relevant alternative.
Conclusion
In clinically node-negative patients, a completion ALND
can be safely omitted if SLNB before NAST is negative
provided good clinical tumor response to NAST. Those
patients with SLNB metastases upfront will receive nodal
staging unaffected by NAST and be consequently offered
adjuvant locoregional treatment according to current
guidelines without the risk of undertreatment. They may
also be enrolled into the Swedish-based SENOMAC trial,
randomizing clinically node-negative patients with up to
two positive SLNs to completion ALND or no further
axillary surgery. A repeat SLNB is not recommended due
to low identification rates and high false negative rates.
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